Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 576 - 600 of 641 in total
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). …
MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as ISS-1018), for use with its vaccine. As of...
Investigational
Matched Description: … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity …
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation. As...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA...
Investigational
Matched Description: … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of …
The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells . This vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention. As...
Investigational
Matched Description: … As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 …
Experimental
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly...
Investigational
Matched Description: … As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity …
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin...
Investigational
Experimental
Matched Name: … 20-hydroxycholesterol …
INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.[A214475, A214478] Follow up studies in both...
Investigational
Matched Description: … (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. ... /2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020
Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Investigational
Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Experimental
Matched Synonyms: … 20(S)-camptothecine …
Matched Iupac: … -hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4,6,8,10,15(20
Investigational
Matched Synonyms: … 5-(2'-hydroxyethoxy)-20(s)-camptothecin …
Matched Iupac: … hydroxyethoxy)-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4,6,8,10,15(20
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
Investigational
Matched Synonyms: … 20-mer complementary to Akt mRNA …
Pegadricase is under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20).
Investigational
Matched Synonyms: … Uricase-PEG 20
Matched Description: … under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20
The KBP-201 COVID-19 Vaccine was developed by British American Tobacco’s (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. As...
Investigational
Matched Description: … As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity …
The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis. Its use has shown clinical improvement, rapid bacterial clearance, and enhanced immune responses to Mycobacterium leprae antigens....
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
Experimental
Matched Name: … Zn(Ii)-(20-Oxo-Protoporphyrin Ix) …
Matched Iupac: … 3-[20-(2-carboxyethyl)-9,14-diethenyl-17-hydroxy-5,10,15,19-tetramethyl-2,22,23,25-tetraaza-1-zincaoctacyclo …
Investigational
Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20)-positive DLBCL Patients).
Investigational
Matched Description: … Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20
Investigational
Matched Iupac: … butoxyethyl)pyridin-1-ium-2-yl]-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20
Investigational
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July...
Investigational
Matched Description: … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the …
Displaying drugs 576 - 600 of 641 in total